02380 408 600
Contact us
Book a course
Home
Conducting Studies
Post-authorisation Safety Studies (PASS)
Event Monitoring Studies
Drug Utilisation Studies
CPRD Studies
Risk Minimisation
European Network Studies
Registries
Flu Vaccine Studies
Study Recruitment
Benefit-Risk Assessment
Systematic Reviews
Consulting
Pharmacovigilance
Pharmacoepidemiology
Consulting for smaller companies
Institute of Pharmacovigilance Sciences
DSRU International Working Group on New Developments in Pharmacovigilance
Methodology Research
DSRU Global Pharmacovigilance Observatory
Education & Training
Our Courses
PgC/PgD/MSc
Conferences
PMST
Testimonials
Customer Portal
Who we are
About Us
Meet The Team
Trustees
Job Vacancies
Information & News
Publications
DSRU News
Blogs
Press
General Practitioners
Conference Abstracts
Menu
×
Home
Conducting Studies
Post-authorisation Safety Studies (PASS)
Event Monitoring Studies
Drug Utilisation Studies
CPRD Studies
Risk Minimisation
European Network Studies
Registries
Flu Vaccine Studies
Study Recruitment
Benefit-Risk Assessment
Systematic Reviews
Consulting
Pharmacovigilance
Pharmacoepidemiology
Consulting for smaller companies
Institute of Pharmacovigilance Sciences
DSRU International Working Group on New Developments in Pharmacovigilance
Methodology Research
DSRU Global Pharmacovigilance Observatory
Education & Training
Our Courses
PgC/PgD/MSc
Conferences
PMST
Testimonials
Customer Portal
Who we are
About Us
Meet The Team
Trustees
Job Vacancies
Information & News
Publications
DSRU News
Blogs
Press
General Practitioners
Conference Abstracts
Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort.
Post navigation
Previous:
Specialist Cohort Event Monitoring Studies: a New Study Method in Risk Management in Pharmacovigilance
Next:
Implications of off-label use: An example from the final results of an observational cohort study on Intrinsa® (testosterone patch).
